Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
- Chris Hourigan Named as New President of Janssen Japan Unit
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
- Eisai to Venture into Chinese Generic Market by Acquiring Local Firm
November 30, 2015
- Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January
November 30, 2015
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
- Viekirax Hits Japan Market, MHLW Orders Rare Label Revision upon Listing
November 27, 2015
- Eisai to Sell Food & Chemical Biz to Mitsubishi Chemical
November 27, 2015
- Sales of Candesartan AGs Miss Half-Year Target on Azilva Switches: ASKA Chief
November 26, 2015
- Japan’s 1st DTP-IPV Vaccine Containing Salk Vaccine to Be Available in December: Daiichi Sankyo
November 26, 2015
- Ex-Exec of Iwaki Subsidiary Embezzled 126 Million Yen
November 25, 2015
- Lilly Files Suit to Bar Launch of Sawai’s Evista Generic
November 24, 2015
- Eisai Gives Global Rights for Selective PDE4 Inhibitor E6005 to US Firm
November 24, 2015
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
- Eisai to Transfer Clinical Diagnostic Business in Japan to Sekisui Chemical for 22.4 Billion Yen
November 24, 2015
- AZ, NCC Link for Non-Clinical Research Utilizing Mass Spectrometry Imaging
November 18, 2015
- Supreme Court Supports Patent Term Extension for Avastin
November 18, 2015
- Boehringer Exec Expects AMED’s Positive Impact on Company
November 18, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…